Latest BPH Stories
All amounts are in U.S. dollars QUEBEC CITY, March 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
Condition known as benign prostatic hyperplasia common in older men SILVER SPRING, Md., March 2 /PRNewswire-USNewswire/ -- The U.S.
Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center.
SOUTHAMPTON, England, February 2 /PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.
Urological Device Market Will Grow to More Than $5.4 Billion VANCOUVER, Jan. 5 /PRNewswire/ - According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S.
CORONA, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc.
QUEBEC CITY, Dec. 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
SEOUL, South Korea, Nov. 18 /PRNewswire/ -- Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).
All amounts are in U.S. dollars QUEBEC CITY, Nov. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
QUEBEC CITY, Sept. 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
- The governor of a province or people.